News & Topics
News&Topics

2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008 / 2007 / 2006 / 2005

2015.12.28
SymBio starts Global Phase 3 Trial for IV Rigosertib
2015.12.24
SymBio Files Supplemental NDA for TREAKISYM® in First-Line Low-grade NHL and MCL
2015.12.24
SymBio Files Supplemental NDA for TREAKISYM® in Chronic Lymphocytic Leukemia (Additional Indication)
2015.12.24
SymBio Files Supplemental NDA for TREAKISYM® in a 25mg Vial (Different Strength)
2015.12.08
Onconova to Present Results from Phase 2 Study of Oral Rigosertib in Combination with Azacitidine for MDS and AML Patients
2015.12.08
Onconova Therapeutics Announces Enrollment of First Patient in Global Phase 3 Trial for IV Rigosertib
2015.12.07
Analyst Report: Shared Research updates the report
2015.12.07
Start of Japan Phase I Combination Clinical Trial of Oral Rigosertib and Azacytidine in Higher-risk MDS
2015.12.01
Analyst Report: Edison updates the report
2015.11.30
Analyst Report: Edison updates the report
2015.11.24
SymBio Partner Announces European Approval of IONSYS®
2015.11.06
Analyst Report: Shared Research updates the report
2015.11.06
Summary of Financial Results For the Third Quarter of Fiscal Year Ending December 31, 2015[Japanese GAAP](Non-consolidated)
2015.11.06
Notice Concerning Non-operating Expenses
2015.10.30
Completion of Japan Phase 1 Clinical Trial for IV Rigosertib in MDS
2015.10.19
Completion of TREAKISYM® Phase II Trial in Chronic Lymphocytic Leukemia
2015.10.19
SymBio to Participate in Global Phase 3 Trial for IV Rigosertib
2015.10.06
The article regarding "Establishment of Strategic Partnership for IONSYS® between The Medicines Company and SymBio" was posted on WSJ
2015.10.05
SymBio and The Medicines Company (Nasdaq: MDCO), announce the establishment of a strategic partnership for IONSYS® (fentanyl iontophoretic transdermal system) in Japan.
2015.09.03
Analyst Report: Shared Research updates the report
2015.08.28
Onconova Announces Submission of European Clinical Trial Applications for IV Rigosertib Pivotal Phase 3 Trial in Higher-Risk MDS
2015.08.17
Onconova to Present Results from Phase 2 Study of Oral Rigosertib in Combination with Azacitidine for MDS and AML Patients
2015.08.17
Onconova Announces Submission of IND for IV Rigosertib Pivotal Phase 3 Trial in Higher-Risk MDS
2015.08.05
Analyst Report: Shared Research updates the report
2015.08.05
Summary of Financial Results For the Second Quarter of Fiscal Year Ending December 31, 2015[Japanese GAAP](Non-consolidated)
2015.08.05
Notice Concerning Non-operating income
2015.06.26
Completion of Japan Phase I Trial for Oral Rigosertib (SyB C-1101) in MDS
2015.05.07
Analyst Report: Shared Research updates the report
2015.05.07
Summary of Financial Results For the First Quarter of Fiscal Year Ending December 31, 2015[Japanese GAAP](Non-consolidated)
2015.05.07
Notice Concerning Non-operating Expense
2015.04.10
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
2015.04.10
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
2015.03.27
Notice of Shareholder Voting Results for the 10th Ordinary General Meeting of Shareholders
2015.03.26
Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Directors
2015.03.26
Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Employees
2015.03.26
Notice of Director and Auditor Appointments
2015.03.23
Analyst Report: Shared Research updates the report
2015.03.18
Notice Concerning Change in Status of Major shareholder
2015.03.06
Information on Shareholders' Meeting: Updated the Page
2015.03.05
Notice of Nomination of Director Candidates and Auditor Candidates
2015.02.12
Analyst Report: Shared Research updates the report
2015.02.10
SymBio's Long Range Plan: FY2015 to FY2017
2015.02.10
Summary of Financial Statements for the Fiscal Year Ended December 31, 2014[Japanese GAAP] (Non-consolidated)
2015.02.10
Notice Concerning Non-Operating Income
2015.02.03
Onconova Announces its Clinical Development Plan for Rigosertib in MDS
2015.01.26
Establishment of Sponsored ADR (American Depositary Receipt) Program
2015.01.13
SEC filings for Establishment of Sponsored ADR (American Depositary Receipt) Program
2015.01.13
Completion of Patient Enrollment of rigosertib (SyB L-1101, IV) Phase I Trial in Patient with refractory or relapsed myelodysplastic syndrome (MDS)